Meanwhile, earnings before interest, tax, depreciation, and amortisation (EBITDA) surged multifold to ₹128 crore, reflecting ...

Wockhardt now intends to file a new drug application (NDA) with the USFDA and seek marketing authorisation application with ...

Zaynich could play a key role in treating patients suffering from complicated urinary tract infections caused by ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Wockhardt share price jumped as much as 4 per cent in early trade on Monday, January 13, defying weak market sentiment. Wockhardt shares opened at ₹1,375.05 against their previous close of ...

is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. Earnings Per Share (TTM ...

What drove Wockhardt share price today? Wockhardt share price jumped in a weak market after it announced through an exchange filing that a life-saving antibiotic developed by it achieves over 97 ...

The Indian drug regulator, Central Drugs Standard Control Organization (CDSCO) has approved Miqnaf (nafithromycin) as a new treatment for the Community-Acquired Bacterial Pneumonia (CABP) in Adults ...

is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period. Earnings Per Share (TTM ...

Wockhardt share price: The stock was last seen trading 1.71 per cent up at Rs 1,099. At this price, it has delivered multibagger returns to investors by rallying 133.85 per cent on a year-to-date ...